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Abstract
 
Immune responses are regulated by opposing positive and negative signals triggered by the in-
teraction of activating and inhibitory cell surface receptors with their ligands. Here, we describe
novel paired activating and inhibitory immunoglobulin-like receptors, designated myeloid-
associated immunoglobulin-like receptor (MAIR) I and MAIR-II, whose extracellular do-
mains are highly conserved by each other. MAIR-I, expressed on the majority of myeloid cells,
including macrophages, granulocytes, mast cells, and dendritic cells, contains the tyrosine-based
sorting motif and the immunoreceptor tyrosine-based inhibitory motif-like sequences in the
cytoplasmic domain and mediates endocytosis of the receptor and inhibition of IgE-mediated
degranulation from mast cells. On the other hand, MAIR-II, expressed on subsets of peritoneal
macrophages and B cells, associates with the immunoreceptor tyrosine-based activation motif-
bearing adaptor DAP12 and stimulates proinflammatory cytokines and chemokine secretions
from macrophages. Thus, MAIR-I and MAIR-II play important regulatory roles in cell signaling
and immune responses.
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Introduction
 
The activating and inhibitory cell surface receptors play im-
portant regulatory roles in immune responses (1, 2). The
immune inhibitory receptors are characterized by a consen-
sus amino acid (aa)
 
*
 
 sequence, immunoreceptor tyrosine-
based inhibitory motif (ITIM), present in their cytoplasmic
domains. The prototype six-aa sequence for ITIM is (I/V/
L/S)-x-Y-x-x-(L/V), where x denotes any aa. Upon ligand
binding, immune inhibitory receptors result in tyrosine
phosphorylation, which provides a docking site for the re-
cruitment of Src homology 2 (SH2)–containing cytoplas-
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Abbreviations used in this paper:
 
 aa, amino acid; FISH, fluorescence in
situ hybridization; ITAM, immunoreceptor tyrosine-based activation
motif; ITIM, immunoreceptor tyrosine-based inhibitory motif; MAIR,
myeloid-associated immunoglobulin-like receptor; MCP-1, monocyte
chemoatractant protein 1; PIR, paired Ig-like receptor; RDA, representa-
tional difference analysis; RT, reverse transcription; SH2, Src homology
2; SHIP, SH2 domain–containing inositol-5–phosphatase. T
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mic phosphatases (3, 4), shutting down activation signals by
dephosphorylation of intracellular substrates at the earliest
steps of the activation response. An expanding family of
immune inhibitory receptors has been identified on a vari-
ety of immune cell types (1).
Recent progress has further demonstrated that many of
these immune inhibitory receptors pair with activating, as
well as inhibitory, isoforms (2, 5), both of whose genes are
located in small clusters on a chromosome (6). For exam-
ple, the NK inhibitory receptor families KIR, CD94/
NKG2, and Ly49, which recognize MHC class I ligands,
contain both activating and inhibitory receptors within the
families (7). The paired activating and inhibitory receptor
families have also been identified on other cell types. The
CD28 and CTLA4 expressed on T cells bind the same
ligands (i.e., CD80 and CD86) yet deliver opposing posi-
tive and negative signals, respectively (8). Similarly, B and/
or myeloid cells express paired receptor families, including
human and murine Fc
 
 
 
 receptors (9, 10), murine paired
Ig-like receptors (PIRs; references 11, 12) and possibly its
human homologue, Ig-like transcripts (ILT; CD85; refer-
ences 13–15), and signal regulatory proteins (16–18). In
contrast to the inhibitory receptors, the activating receptors
have a short cytoplasmic domain lacking ITIM but con-
taining a charged aa residue in the transmembrane region,
which is involved in association with immunoreceptor
tyrosine-based activation motif (ITAM)–bearing adaptor
transmembrane proteins, such as Fc
 
 
 
RI
 
 
 
 or DAP12, or
with DAP10 adaptors containing PI3 kinase binding motif
(19, 20). Among these activating and inhibitory receptors,
KIR, PIR, ILT, and signal regulatory proteins belong to
the Ig supergene family, which is characterized by the ex-
tracellular portion containing Ig-like domain, in some cases
binding the same ligands that are highly homologous to
each other (2, 6). The genes encoding most of these recep-
tors are located on human chromosome 19q13.4 or its syn-
tenic region on murine chromosome 7 (6).
In the present investigation, we have identified novel
paired activating and inhibitory Ig-like receptors, desig-
nated myeloid-associated immunoglobulin-like receptor
(MAIR) I and MAIR-II, expressed on the majority of
macrophages, granulocytes, dendritic cells, mast cells, and a
subset of B cells. Here, we describe the molecular and
functional characteristics of the MAIR.
 
Materials and Methods
 
Antibodies.
 
Control rat and mouse IgGs, anti–mouse TCR
 
 
 
,
CD45R/B220, CD11b (Mac1), CD11c, Ly6G (Gr-1), CD21,
CD23, and CD32/16 mAbs and DX-5 mAb were purchased
from BD Biosciences; antiphosphotyrosine (4G10) and anti-
Fc
 
 
 
RI
 
 
 
 mAbs were purchased from Upstate Biotechnology;
anti-Flag mAb was purchased from Sigma-Aldrich; anti–SHP-1,
anti–SHP-2, and anti–SH 2 domain–containing inositol-5–phos-
phatase (SHIP) antibodies were purchased from Santa Cruz Bio-
technology, Inc.; and rat IgE anti-DNP mAb was purchased
from Zymed Laboratories. Anti-DAP12 polyclonal antibody was
a gift from M. Ono (Ehime University School of Medicine,
Ehime, Japan). TX-8 (anti–MAIR-I), TX-10 (anti–MAIR-I and
MAIR-II), and TX-13 (anti–MAIR-II) mAbs were generated in
our laboratory by fusing the Sp2/0 myeloma cell line with
popliteal lymph node cells from rats that had been immunized by
injection of Ba/F3 transfectants expressing the MAIR-I or
MAIR-II, and each extracellular protein was fused with the Fc
portion of human IgG into footpads, as described previously
(21). F(ab
 
 
 
)
 
2
 
 fragments were prepared by digesting TX-8 and
TX-13 mAbs with immobilized pepsin (10 mg IgG in 10 ml of
0.2 M sodium citrate, 0.15 M NaCl buffer, pH 3.5, with 2.5 ml
of immobilized pepsin for 1 h at 37
 
 
 
C; Pierce Chemical Co.),
and afterwards, by removing residual intact mAb by protein A af-
finity chromatography. Purity of the F(ab
 
 
 
)
 
2
 
 fragments were de-
termined by SDS-PAGE.
 
Representational Difference Analysis (RDA) and cDNA Cloning.
 
Total RNA was isolated using Isogen LS solution (Nippon
Gene), and oligo(dT)-primed double-stranded cDNA was syn-
thesized using a cDNA synthesis system (GIBCO BRL) accord-
ing to the manufacturer’s instructions. RDA was performed, as
described previously (22), using day 14 fetal livers from wild-type
and PU.1
 
 
 
/
 
 
 
 mice. Full-length 
 
MAIR-Ia
 
 cDNA was cloned by
screening of a macrophage cDNA library, using a cDNA frag-
ment generated by RDA as a probe. Full-length 
 
MAIR-Ib
 
,
 
MAIR-IIa,
 
 and 
 
MAIR-IIb
 
 cDNAs were also isolated by screening
the same cDNA library, using the extracellular domain of 
 
MAIR-
Ia
 
 cDNA as a probe.
 
Northern Blot Analysis. MAIR-I
 
 cDNA was labeled with
[
 
32
 
P]dCTP using the Ready to Go DNA Labeling Beads (Amer-
sham Biosciences). Membranes containing 
 
 
 
10 
 
 
 
g of total RNA
in each lane from different mouse tissues were hybridized with
the [
 
32
 
P]dCTP–labeled cDNA probes at 68
 
 
 
C in modified
Church’s hybridization buffer (0.5 M Church’s phosphate buffer,
7% SDS, and 1% BSA). The membranes were washed at 68
 
 
 
C for
1 h in Church’s washing buffer (40 mM Church’s phosphate
buffer and 1% SDS) and developed by autoradiography.
 
Reverse Transcription(RT)–PCR.
 
RNA was subjected to RT
and PCR using 
 
MAIR-I
 
–specific primers (5
 
 
 
-GCTGATAG-
GCATCCAGAGC-3
 
 
 
 and 5
 
 
 
-AAGGAGTCACAGGTAAAG-
GTC-3
 
 
 
), 
 
MAIR-II
 
–specific primers (5
 
 
 
-TCGAGCCTTGA-
GAGTGGTAGAC-3
 
 
 
 and 5
 
 
 
-AGGAGCTGTGTTTAGGGA-
CAG-3
 
 
 
), DAP12-specific primers (5
 
 
 
-GGCTCTGGAGCCC-
TCCTGGT-3
 
 
 
 and 5
 
 
 
-CTGTGTGTTGAGGTCACTG-3
 
 
 
), or
 
HPRT
 
-specific primers (5
 
 
 
-GCTGGTGAAAAGGACCTCT-3
 
 
 
and 5
 
 
 
-CACAGGACTAGAACACCTGC-3
 
 
 
). The amount of
cDNA was normalized by the quantitative PCR using TaqMan
rodent GAPDH control reagent (Applied Biosystems; reference
23). Conditions used for PCR were as follows: 30 or 35 cycles of
20-s denaturation (94
 
 
 
C), 20-s annealing (55
 
 
 
C), and 30-s exten-
sion (72
 
 
 
C).
 
Fluorescence in Situ Hybridization (FISH).
 
The direct R-band-
ing FISH method was used for chromosomal assignment of the
 
MAIR-I
 
 gene in mouse and rat. Preparation of R-banded chro-
mosomes and FISH were performed, as described by Matsuda et
al. (24) and Matsuda and Chapman (25).
 
Establishment of Transfectants Expressing MAIR-I or MAIR-II.
 
The 
 
MAIR-I
 
 and 
 
MAIR-II
 
 cDNA tagged with the flag cDNA at
the NH
 
2
 
 terminus were subcloned into the pMX retroviral vec-
tors (26). To generate site-directed MAIR-I mutant at residues
Y
 
233
 
, PCR primers, which contained a codon for F
 
233
 
 (TTT) in-
stead of Y
 
233
 
 (TAT), were designed. BW5147, Ba/F3, and RAW
cells stably expressing Flag-tagged MAIR-I and MAIR-II were
established as described previously (27).
 
Serotonin-release Assay.
 
Bone marrow cells obtained from the
femur and tibia of adult Balb/c mice were cultured at a concen-T
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tration of 2 
 
 
 
 10
 
5
 
 cells/ml in RPMI 1640 medium containing
10% FBS, 4 ng/ml mouse rIL-3 (BD Biosciences), and 10 ng/ml
mouse rSCF (provided by KIRIN). The bone marrow–derived
nonadherent cells were transferred weekly into new culture
dishes over a 4–10-wk culture interval. Ig-E–mediated serotonin
release assay was performed as described previously (28). In
brief, bone marrow–derived mast cells were incubated with 5
 
 
 
Ci/ml [
 
3
 
H]serotonin (5-[1,2-
 
3
 
H(
 
N
 
)]-hydroxytryptamine creat-
inine sulfate; NEN Life Science Products) for 5 h at 37
 
 
 
C,
washed, and reincubated for an additional 1 h to reduce back-
ground radioactivity. [
 
3
 
H]Serotonin-loaded mast cells were
plated in 96-well plates that contained 10 
 
 
 
l of rat IgE, 25 
 
 
 
g/
ml anti-DNP mAb, and various concentrations of F(ab
 
 
 
)
 
2
 
 frag-
ments of rat anti–MAIR-I or control IgG, incubated for 30 min
at 4
 
 
 
C, washed, and resuspended in 25 
 
 
 
l of culture medium.
Antibody-primed mast cells were challenged with 25 
 
 
 
l of
F(ab
 
 
 
)
 
2
 
 fragments of 40 
 
 
 
g/ml rabbit anti–rat Ig antibody for
30–60 min at 37
 
 
 
C. The reactions were terminated by adding 50
 
 
 
l of cold PBS. [
 
3
 
H]Serotonin in the supernatants were mea-
sured by a liquid scintillation counter.
 
Internalization Assay.
 
Peritoneal macrophages were incu-
bated with biotin-labeled anti–MAIR-I mAb (TX-8), followed
by allophycocyanin-labeled streptavidin at 4
 
 
 
 or 37
 
 
 
C for 30 min.
Cells were treated or not with 2.5% trypsin and analyzed by flow
cytometry. Ba/F3 transfectants expressing Flag-tagged MAIR-I at
the NH
 
2
 
 terminus were incubated with anti-Flag mAb, followed
by cross-linking with FITC-labeled anti–mouse IgG secondary
antibody at 4
 
 
 
C. Cells were resuspended in RPMI 1640 contain-
ing 10% FBS, plated onto polylysine-precoated chamber slide
(Lab-Tek II; Nunc) and incubated at 37
 
 
 
C for 30 min. Cells were
centrifuged at 1,500 rpm for 5 min at 4
 
 
 
C, washed with PBS
twice, and fixed with 3% paraformaldehyde. Cells were mounted
with VECTASHIELD including DAPI (Vector) and analyzed
under a confocal scanning laser microscope.
 
Biochemistry.
 
BW5147 transfectants expressing Flag-tagged
MAIR-I or -II were lysed in Tris-buffered saline (50 mM Tris
and 15 mM NaCl, pH 8.0) containing 1% NP-40, protease in-
hibitors (1 mM PMSF and 20 Kallikrein inhibitor U/ml aproti-
nin), and phosphatase inhibitors (1 mM EGTA, 10 mM NaF,
1 mM Na
 
4
 
P
 
2
 
O
 
7
 
, 0.1 mM 
 
 
 
-glycerophosphate, and 1 mM
Na
 
3
 
VO
 
4
 
). To examine 
 
N
 
-glycosylation of MAIR-I, lysates of
BW5147 transfectants expressing Flag-tagged MAIR-I were im-
munoprecipitated with anti-Flag mAb or control Ig and treated
or not with 
 
N
 
-glycosidase F (Boehringer) using the conditions
recommended by the manufacturers. To examine tyrosine phos-
phorylation of MAIR-I or association of MAIR-I with phos-
phatases, mast cells were stimulated or not with 100 mM sodium
pervanadate for 10 min at 37
 
 C. Cells were lysed in 1% digitonin
(Sigma-Aldrich) buffer (0.12% Triton X-100; Katayama Pure
Chemical), 150 mM NaCl, 20 mM triethanolamine (Katayama
Pure Chemical), or 1% NP-40 buffer, containing the protease
and phosphatase inhibitors. For analysis of association of MAIR-
II with DAP12 or Fc RI , 293T or RAW transfectants express-
ing MAIR-II or B cells separated from spleen cells were lysed in
1% digitonin buffer, and cell lysates were immunoprecipitated
with control Ig, anti-DAP12, or anti-Fc RI .
Lysates or immunoprecipitates were separated by SDS-PAGE,
transferred (100 V, 1 h in 25 mM Tris, 195 mM glycine, and 20%
methanol) to PVDF membranes (Immobilon-P; Millipore).
Membranes were incubated overnight in Tris-buffered saline
containing 0.5% Tween 20, MgCl2, and 3% BSA at 4 C, and in-
cubated with primary antibodies (1 µg/ml in Tris-buffered saline
with 3% BSA) for 2 h at room temperature. Proteins were de-
tected by using HRP-conjugated goat anti–mouse, anti–rat, or
anti–rabbit Igs (Amersham Biosciences), and were developed
with SuperSignal CL-HRP substrate (Pierce Chemical Co.).
Chemiluminescences were detected by autoradiograph or image
analyzer (LAS model 1000 mini; Fuji Film).
ELISA. RAW cells expressing Flag-tagged MAIR-II or
peritoneal macrophages derived from C57BL/6 mice were pre-
treated with anti–CD32/16 (Fc R) to block Fc  receptors, stim-
ulated with plastic-coated control Ig, anti-Flag, or anti–MAIR-II
mAb, and cultured for 24 or 48 h. TNF- , IL-6, and monocyte
chemoatractant protein 1 (MCP-1) concentrations in culture su-
pernatants were measured using an ELISA kit (eBioscience) ac-
cording to the manufacturer’s instructions.
Results
Cloning and Molecular Characteristics of MAIR-I and
MAIR-II. To identify novel genes involved in immune
responses by myeloid cells, we performed representational
differential analysis (RDA), which is a PCR-based subtrac-
tive hybridization, using day 14 fetal livers from PU.1 / 
mice lacking myeloid cells and control littermates. We
identified several cDNA clones unique to myeloid cells.
Full-length cDNAs were cloned by screening a macro-
phage cDNA library. The predicted aa sequence demon-
strates that the protein encoded by one of these cDNAs is a
type-1 transmembrane protein with a 27-aa leader se-
quence, a 152-aa extracellular domain, a 23-aa transmem-
brane domain, and a 112-aa cytoplasmic region (Fig. 1 A).
A pair of cysteine residues in the extracellular domain is
flanked by consensus sequences for one Ig-like domain, in-
dicating that the protein, designated MAIR-Ia, is a mem-
ber of the Ig superfamily. The extracellular domain has one
potential site for N-linked glycosylation, suggesting that
MAIR-Ia is a glycoprotein. The cytoplasmic domain con-
tains the five tyrosines at residues 233, 258, 270, and
299. Among these tyrosines, the residues at 258 and 270
may consist of ITIM-like sequences (VEY258STL and
LHY270SSV, respectively) based on the consensus sequence
for ITIMs (I/V/L/SxYxxL/V), suggesting that MAIR-I
may recruit protein tyrosine phosphatases and mediate in-
hibitory signals. We found that the motif Y233VNL is also a
consensus sequence involved in receptor internalization
(29, 30).
To examine whether MAIR-Ia is a member of paired
activating and inhibitory receptors, we further screened the
macrophage cDNA library using the cDNA encoding ex-
tracellular domain of MAIR-Ia as a probe. We identified a
clone encoding the protein, designated MAIR-IIa, which
contains one Ig-like domain with 92% aa identity to that of
MAIR-Ia in extracellular domain, a transmembrane region
with a charged (Lys aa) and a short (20 aa) cytoplasmic tail
(Fig. 1, A and B). In addition, we found the isoforms
of MAIR-Ia and MAIR-IIa, designated MAIR-Ib and
MAIR-IIb, which contain additional four and two aas, re-
spectively, in the extracellular domain. These are alternate
splicing variants of MAIR-Ia and MAIR-IIa, as suggested by
the genomic DNA sequence of MAIR-I and MAIR-II (un-
published data). Southern blot analysis of murine genomicT
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Figure 1. Molecular and biochemical characteristics of MAIR-I and MAIR-II. (A) Pre-
dicted aa sequences of MAIR-I and MAIR-II. The putative leader and transmembrane do-
main are underlined. Potential N-linked glycosylation sites in the extracellular domain and
the charged aa residue in the transmembrane region are circled. Potential cysteine residues
involved in disulfide bonding of the Ig-like domains are indicated in bold. ITIM-like or
sorting motif in the cytoplasmic domain are boxed. The cDNA sequence data are available
from GenBank/EMBL//DDBJ under accession nos. AB091765, AB091766, AB091767,
and AB091768 (MAIR-Ia, MAIR-Ib, MAIR-IIa, and MAIR-IIb, respectively). (B) Schematic
diagram of MAIR-I and MAIR-II proteins. A pair of cysteine residues in the extracellular
portion potentially able to participate in intrachain disulfide bonding for the formation of
Ig-like domains are indicated. (C) Southern blot analysis of genomic MAIR-I and MAIR-II.
Mouse genomic DNA was digested with the indicated enzymes (E, EcoRI; B, BamHI; H, HindIII; X, XbaI; and P, PstI) and probed with the cDNA
encoding the extracellular portion of MAIR-I. (D) BW5147 cells expressing the Flag-tagged MAIR-I or MAIR-II were lysed and proteins were ana-
lyzed by immunoblotting with anti-Flag mAb under reducing and nonreducing conditions. (E) BW5147 cells expressing the Flag-tagged MAIR-I or
parental BW5147 cells were lysed and proteins were immunoprecipitated with anti-Flag. Precipitates were treated or not with N-glycosidase F and
immunoblotted with anti-Flag mAb under nonreducing conditions.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
227 Yotsumoto et al.
DNA, using the cDNA encoding the conserved Ig-like do-
main in the extracellular domain of MAIR-I and MAIR-
II, demonstrated a simple hybridization pattern, suggesting
that each MAIR-I and MAIR-II is encoded by a single
gene (Fig. 1 C). The MAIR-I and MAIR-II genes are lo-
cated to the proximal region of the E2 band of mouse
chromosome 11 and consist of six and four exons, respec-
tively, as determined by FISH and a genomic DNA se-
quence database (unpublished data). Database search dem-
onstrated that MAIR-I and MAIR-II are most similar to
human CMRF-35-H9 (31) with 44% homology and to
human CMRF-35 (31) with 49% homology, respectively.
Moreover, both CMRF-35-H9 and CMRF-35 genes are
located near to human chromosome 17, syntenic region of
mouse chromosome 11 (32), suggesting that these are the
human homologues to murine MAIR-I and MAIR-II.
Mouse T cell leukemia BW5147 cells were transfected
with the MAIR-Ia and MAIR-IIa cDNAs tagged with Flag
peptide at the NH2 terminus, which resulted in surface ex-
pression of the receptor as detected by immunofluores-
cence using an anti-Flag mAb (unpublished data). Im-
munoprecipitation of the Flag-tagged MAIR-Ia and
MAIR-IIa receptors on the BW5147 transfectants with
an anti-Flag mAb revealed  50 and  35 kD proteins, re-
spectively, when analyzed under both reducing and non-
reducing conditions (Fig. 1 D). The mobility of MAIR-Ia
decreased from  50 to  45 kD after treatment with
N-glycosidase F, which is consistent with the size of the
polypeptide predicted from the MAIR-I cDNA and the
presence of one potential N-linked glycosylation site in
the extracellular domain (Fig. 1 E).
Expression of MAIR-I and MAIR-II. Northern blot
analysis using the full-length MAIR-Ia cDNA, containing
the conserved cDNA sequence of the MAIR-I and MAIR-
II, as a probe demonstrated that MAIR-I and/or MAIR-II
transcripts were detected in lymphohematopoietic tissues,
including spleen and bone marrow, but not in thymus and
nonhematopoietic organs (Fig. 2 A). We also observed that
peritoneal macrophages express significant amount of
MAIR transcripts, which were up-regulated in these cells
after in vivo stimulation with thioglycollate. The preferen-
tial expression of MAIR transcript was also observed in my-
eloid cell lines, including 416B, WEHI3, RAW, and M1
cells (Fig. 2 A).
To further analyze the expression of the MAIR-I and
MAIR-II on hematopoietic cells, RNA was obtained from
lymphohematopoietic progenitors and lineage-committed
cells purified by flow cytometry from the bone marrow,
thymus, and spleen. RT-PCR analysis using the specific
primers for MAIR-I and MAIR-II demonstrated that both
the transcripts were expressed in multilineage cells, includ-
ing lymphohematopoietic progenitors, granulocytes, mac-
rophages, erythroid cells, and B cells in bone marrow, and
in T, B, and NK1.1  cells in the spleen. However, neither
of the MAIR-I and MAIR-II transcripts was detected in im-
mature and mature T cells in the thymus (Fig. 2 B).
To examine the cell surface expression of the MAIR-I
and MAIR-II proteins, we generated monoclonal antibod-
ies TX-8 and TX-13, which preferentially react to MAIR-I
and MAIR-II, respectively (Fig. 3 A). Analysis of spleen
and bone marrow cells by flow cytometry showed that
MAIR-I is expressed on the majority of myeloid cells, in-
cluding macrophages, dendritic cells, granulocytes, and
bone marrow–derived cultured mast cells, and MAIR-1 is
expressed on a subset of B cells, but neither on T nor NK
cells (Fig. 3, B and D). In contrast, MAIR-II protein is de-
tected only on cell surface of subsets of B cells and perito-
neal macrophages (Fig. 3, B and E). These results indicated
that the transcript’s expressions of MAIR-I and MAIR-II
do not always result in cell surface expression of the pro-
teins. To further characterize the B cell subsets expressing
MAIR-I or MAIR-II, spleen cells were simultaneously
stained with anti-CD21 and anti-CD23 mAbs in combina-
tion with either anti–MAIR-I or anti–MAIR-II. The mar-
ginal zone B cells that are characterized by cell surface
phenotype of CD21hiCD23lo express higher amount of
MAIR-I and MAIR-II than the CD21intCD23hi follicular
B cells (Fig. 3 C; reference 33). These results suggest that
marginal zone B cells consist of the major population of
MAIR-II expressing B cell subset in spleen.
To examine regulatory mechanisms of the proteins ex-
pression on cell surface, purified B cells from spleen were
cultured in medium in the presence or absence of LPS, re-
sulting in a significant up-regulation of MAIR-II on the
cell surface in both the culture condition (Fig. 3 F), al-
though we did not observe any modulation of MAIR-I
and MAIR-II proteins expressions on macrophages from
spleen in the same culture condition (not depicted). Al-
though no MAIR-I and MAIR-II proteins were detected
on the NK cell surface despite the abundant presence of
Figure 2. Expression of MAIR-I and MAIR-II transcripts. (A) Expres-
sion of MAIR-I and/or MAIR-II transcripts was analyzed by Northern
blot analysis using cDNA encoding MAIR-I extracellular portion as a
probe. The comparable amount of  -actin transcript expression in each
lane using  -actin cDNA was confirmed (not depicted). (B) cDNA, ad-
justed to comparable quantities using a HPRT control, was prepared from
purified cells by cell sorter, as indicated. These cDNA and water (used as a
negative control) were used as templates for RT-PCR. PCR products
were amplified using specific primers for MAIR-I and MAIR-II.T
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Figure 3. Cell surface expression of MAIR-I and MAIR-II proteins. (A) BW5147 transfectants expressing MAIR-I or MAIR-II were stained with
control rat Ig or anti–MAIR-I (TX-8 mAb) or anti–MAIR-II (TX-13 mAb), followed by allophycocyanin-conjugated streptavidin. (B, D, and E)
Spleen, bone marrow, or peritoneal macrophages from C57/BL6 mice were stained with either biotin-conjugated F(ab )2 fragments of anti–MAIR-I or
anti–MAIR-II and the PE-conjugated mAbs indicated, followed by allophycocyanin-conjugated streptavidin. Greater than 99% of cells stained with
F(ab )2 fragments of control Igs were present in the bottom left quadrant of the contour plots (B and D, and not depicted in C). (C) Spleen cells were
stained with FITC-conjugated anti-CD21, PE-conjugated anti-CD23, and biotin-conjugated anti–MAIR-II monoclonal antibodies, followed by allo-
phycocyanin-conjugated streptavidin. MAIR-I and MAIR-II expression on the CD21hiCD23lo (marginal zone B cells [MZB]) and CD21intCD23hi
(follicular B cells [FOB]) cells were analyzed by flow cytometry. (E) B220  B cells purified from splenocytes or total splenocytes were cultured for 48 h
or not in the presence or absence of LPS or IL-12, as indicated, and stained with either biotin-conjugated F(ab )2 fragments of control Ig, anti–MAIR-I
or anti–MAIR-II and the FITC-conjugated B220 or DX5 mAb, followed by allophycocyanin-conjugated streptavidin. Cells were gated according to
B220 or DX5 expressions and analyzed by flow cytometry. Data are representative in several independent experiments.T
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their transcripts, IL-12 stimulated cell surface expression of
MAIR-I, but not MAIR-II, on NK cells (Fig. 3 F).
MAIR-I Mediates Endocytosis. The cytoplasmic do-
main of the MAIR-I contains a possible tyrosine-based
sorting motif (Fig. 1 A, YVNL), implicated in endosome
and lysosome targeting of diverse proteins and involved in
agonist-induced internalization (29, 30). To investigate
whether the MAIR-I internalizes upon cross-linking,
MAIR-I expressed on peritoneal macrophages were
cross-linked with anti–MAIR-I mAb and incubated at 4
or 37 C for 1 h. Some of the cells were treated with
trypsin to remove the cell surface MAIR-I that did not
undergo internalization. Treatment with trypsin signifi-
cantly decreased the fluorescence intensity of the cells,
which were incubated at 4 C after cross-linking (Fig. 4
A). By contrast, the fluorescence remained constant in the
cells, which were incubated at 37 C after cross-linking,
despite treatment with trypsin. This suggests that cross-
linking the MAIR-I induced the receptor internalization
during culture at 37 C. To confirm MAIR-I internaliza-
tion upon cross-linking, the Ba/F3 transfectants express-
ing the Flag-tagged MAIR-I at the NH2 terminus were
incubated with anti-Flag mAb, cross-linked with FITC-
labeled secondary antibody, and incubated at 37 C for 30
min. Although green fluorescence was detected only at
the cell surface before incubation, it was abundantly ob-
served in the cytoplasm of the transfectants 30 min after
incubation at 37 C under confocal scanning laser micro-
scope (Fig. 4 B), indicating that MAIR-I underwent in-
ternalization after cross-linking. In contrast, we did not
detect internalization of the MAIR-I mutated at the tyro-
sine residue 233 (Y-F233) in the sorting motif (Fig. 4 B),
indicating that the tyrosine at residue 233 is responsible
for the MAIR-I internalization.
MAIR-I Recruits the Tyrosine Phosphatase SHIP. The
existence of the ITIM-like sequences in the cytoplasmic
region of MAIR-I suggested that MAIR-I is tyrosine phos-
phorylated and may recruit SH2-containing tyrosine phos-
phatases. Therefore, we first examined whether MAIR-I
expressed on bone marrow–derived cultured mast cells
were tyrosine phopshorylated by the stimulaion with per-
vanadate. As demonstrated in Fig. 5 A, stimulation with
pervanadate significantly induced tyrosine phosphorylation
of the MAIR-I (Fig. 5 A). Immunoprecipitation of the
protein tyrosine phosphatases, SHP-1 and SHP-2, and
SHIP demonstrated that MAIR-I associated with SHIP,
but not SHP-1 and SHP-2, upon stimulation of mast cells
with pervanadate (Fig. 5 B). These results suggest that
MAIR-I may mediate inhibitory signal upon phosphoryla-
tion of the tyrosines in the cytoplasmic region.
MAIR-I Inhibits IgE-mediated Serotonin Release from Mast
Cells. To address a functional role of MAIR-I in immune
responses, mast cells were loaded with [3H]serotonin and
stimulated with an IgE mAb plus F(ab )2 fragments of anti–
MAIR-I mAb, followed by coligation with a common sec-
ondary reagent. As demonstrated in Fig. 5 C, cross-linking
MAIR-I with anti–MAIR-I mAb inhibited IgE-mediated
serotonin release from bone marrow–derived mast cells in
a dose-dependent manner. These results indicate that
MAIR-I transduces an inhibitory signal, resulting in sup-
pression of mast cell degranulation triggered by Fc RI-
mediated activation signals.
MAIR-II Associates with DAP12. In contrast to
MAIR-I, MAIR-II has a short cytoplasmic tail and a posi-
tively charged aa residue in the transmembrane domain.
To test a noncovalent association of MAIR-II with an
adaptor transmembrane protein, such as the Fc RI  or
DAP12, 293T cells, which express neither Fc RI  nor
DAP12, were transfected with MAIR-II cDNA and either
Fc RI  or DAP12. The transfectants were lysed in 1% dig-
itonin buffer and immunoprecipitated with anti-Fc RI 
or anti-DAP12, and the isolated proteins were analyzed by
immunoblotting with anti–MAIR-II. As demonstrated in
Fig. 6 A, MAIR-II was coimmunoprecipitated with
DAP12, but not with Fc RI , suggesting the physical as-
sociation of MAIR-II with DAP12. Similary, MAIR-II
Figure 4. Internalization of MAIR-I. (A) Peritoneal macrophages were
incubated with biotin-labeled anti–MAIR-I mAb (TX-8), followed by al-
lophycocyanin-labeled streptavidin at 4 or 37 C for 30 min. The cells
were treated ( ) or not ( ) with trypsin and analyzed by flow cytometry.
(B) Ba/F3 transfectants expressing Flag-tagged wild-type and mutated
MAIR-I were incubated with anti-Flag mAb, followed by cross-linking
with FITC-labeled anti–mouse IgG secondary antibody at 4 C. Cells were
incubated or not at 37 C for 30 min, fixed, mounted with VECTASHIELD
including DAPI, and analyzed using a confocal scanning laser microscope.
Data are representative in several independent experiments.T
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was also coimmunoprecipitated with endogenous DAP12,
but not Fc RI , in the lysates of mouse macrophage cells
RAW after transfection with MAIR-II alone (Fig. 6 B). To
confirm the physiological association of MAIR-II with
DAP12 in primary cells, spleen cells were stimulated with
LPS for 48 h, resulting in the up-regulation of MAIR-II
expression of B cells and macrophages (unpublished data).
The stimulated spleen cells were lysed in 1% digitonin
buffer and immunoprecipitated with anti-Fc RI  or anti-
DAP12. Immunoblotting of the isolated proteins with
anti–MAIR-II again demonstrated the coimmunoprecipi-
tation of MAIR-II with the DAP-12, but not with the
Fc RI  (Fig. 6 C), indicating that DAP12 is the physio-
logical partner for MAIR-II of stimulated B cells and/or
macrophages in the spleen. These results were in agree-
ment with the observation that DAP12 expression on cell
surface of 293T cells depended on the expression of
MAIR-II, although MAIR-II does not require DAP12 for
cell surface expression (Fig. 6 D).
MAIR-II Stimulates Proinflamatory Cytokines and Chemo-
kine Secretions from Macrophages. Because macrophages
abundantly express DAP12 (34), we investigated a func-
tional role of MAIR-II–mediated signaling in immune re-
sponses by macrophages. Macrophage cells, RAW, were
transfected with Flag-tagged MAIR-II cDNA at the NH2
terminus and stimulated with control Ig or anti-Flag.
Cross-linking MAIR-II with anti-Flag significantly stimu-
lated the production of TNF-  from the transfectants (Fig.
7). We further examined whether MAIR-II mediates
TNF-  secretion from primary macrophages from peri-
toneal cavity. As shown in Fig. 7, TNF-  secretion
from  peritoneal macrophages was significantly increased
upon cross-linking of MAIR-II. Similarly, engagement of
MAIR-II stimulated IL-6 and MCP-1 secretions from
peritoneal macrophages (Fig. 7). However, we did not ob-
serve a significant increase of IL-12 secretion from perito-
neal macrophages after cross-linking MAIR-II (unpub-
lished data). These results suggest that MAIR-II mediates
activation signal in macrophages, leading to cytokine and
chemokine secretion from macrophages.
Figure 5. MAIR-I recruits the tyrosine phosphatase SHIP and inhibits serotonin release from mast cells. (A and B) Mast cells, derived from bone
marrow cells after culture in the presence of IL-3 and stem cell factor (SCF), were stimulated or not with pervanadate for 10 min at 37 C and lysed in 1%
NP-40 (A) or digitonin (B) buffer and immunoprecipitated with cIg, anti–MAIR-I, anti–SHP-I, anti–SHP-II, or anti-SHIP. The immunoprecipitates
were immunoblotted with antiphosphotyrosine mAb (A) or anti–MAIR-I (B). (C) Mast cells were loaded with [3H]serotonin and stimulated with an IgE
mAb plus either F(ab )2 fragments of anti–MAIR-I or control rat IgG, followed by coligation with a common secondary reagent. [3H]Serotonin release
into the supernatants was measured by a liquid scintillation counter. Data are representative in several independent experiments.
Figure 6. Physical association of MAIR-II with DAP12. (A–C) 293T and RAW cells, which were transfected with cDNA as indicated, and spleen
cells after stimulation with LPS were lysed in digitonin buffer, immunoprecipitated with control Ig, anti-DAP12, or anti-Fc RI , and immunoblotted
with anti–MAIR-II (TX-10). (D) 293T cells were transfected with Flag-tagged DAP12, MAIR-II, or a combination of Flag-tagged DAP12 and MAIR-II,
and stained with biotin-conjugated anti–MAIR-II and FITC-conjugated anti-Flag mAbs, followed by allophycocyanin-conjugated streptavidin. Cell sur-
face expression of MAIR-II and DAP12 was analyzed by flow cytometry.T
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Expression of DAP12 in B Cells. Although human pri-
mary B cells and a mouse B cell line also express DAP12
transcript (35, 36), there has been no paper reporting that
primary mouse B cells express DAP12. To investigate the
functional role of MAIR-II on B cells, we examined
whether spleen B cells express DAP12. B cells were highly
fractionated from spleen cells stimulated with LPS accord-
ing to MAIR-II expression by repeating sorting on flow
cytometry ( 99.8% purity, as determined by reanalysis by
flow cytometry) and subjected to semiquantitative RT-
PCR. As demonstrated in Fig. 8 A, both fractions of B cells
express DAP12 transcript. To further examine whether B
cells express DAP12 protein, DAP12 was immunoprecipi-
tated from purified B cells before or after stimulation with
LPS for 24 h and immunoblotted with anti-DAP12. Al-
though DAP12 protein was undetectable in primary resting
B cells, we observed a significant up-regulation of DAP12
protein expression in stimulated B cells (Fig. 8 B). These
results suggest that MAIR-II associates with DAP12 (also
on B cells, at least in the activated state with LPS), resulting
in MAIR-II–mediated signaling in B cells.
Discussion
Paired activating and inhibitory Ig-like receptors have
attracted widespread interest because they are expressed on
a variety of immune cell types and facilitate activation or
deactivation of immune responses. Although most genes
encoding these receptors are located on human chromo-
some 19q13.4 or its syntenic region on murine chromo-
some 7 (6), MAIR-I and MAIR-II genes are mapped to a
unique location on murine chromosome 11E2, suggesting
that the MAIR is a novel family of paired activating and in-
hibitory receptors.
The regulatory mechanism of paired activating and in-
hibitory receptor expressions on the cell surface is quite an
important concept to be clarified; these receptors may play
opposite roles in immune responses upon binding to their,
sometimes common, ligand(s). However, their protein ex-
pression profiles on immune cells remain largely unknown,
mainly because of lacking mAbs which distinguish between
these paired receptors containing highly conserved extra-
cellular domains each other. This is the case also in
CMRF-35-H9 and CMRF-35 (31), possible human ho-
mologues of MAIR-I and MAIR-II, respectively.
In this paper, we have analyzed expressions of MAIR-I
and MAIR-II using TX-8 and TX-13 mAbs that specifi-
cally react to MAIR-I and MAIR-II, respectively, demon-
strating that MAIR-I is expressed on the majority of all the
myeloid lineage cells and a subset of B cells, whereas
MAIR-II is expressed only on subsets of B cells and perito-
neal macrophages (Fig. 3, B, C, and D). This suggests that
the MAIR-I inhibitory receptor is always dominantly ex-
pressed on these cells. These findings were not in complete
agreement with the results of transcript expression, which
indicated that both MAIR-I and MAIR-II are similarly ex-
pressed in the multilineage immune cells (Fig. 2 B). How-
ever, we have demonstrated that MAIR-II protein expres-
sion on B cell surface is up-regulated after culture (Fig. 3
E). Similarly, MAIR-I expression was also up-regulated on
NK cells after stimulation with IL-12. We have also shown
the down-regulation of MAIR-I cell surface expression by
the receptor internalization upon cross-linking (Fig. 4). Al-
though physiological significances of the up-regulation of
MAIR-I and MAIR-II expression and the down-regula-
tion of MAIR-I expression on cell surface are uncertain at
present, they may play a regulatory role in cell activation
when these receptors encounter their ligand(s). Further
studies on the regulatory mechanisms of MAIR-I and
Figure 7. MAIR-II stimulates cytokines and chemokines secretion
from macrophages. RAW cells transfected with Flag-tagged  MAIR-II
cDNA at the NH2 terminus and peritoneal macrophages were pretreated
with anti-CD16/32 (Fc  receptors) to block Fc binding of mAbs, stimu-
lated with plastic-coated control Ig, anti-Flag, or anti–MAIR-II, and
cultured for 48 h. Culture supernatants were harvested, and cytokine’s
and chemokine’s concentrations were measured by ELISA.
Figure 8. Expression of DAP12 in B cells. (A) Spleen cells were stained
with biotin-conjugated anti–MAIR-II and PE-conjugated B220, fol-
lowed by allophycocyanin-conjugated streptavidin. MAIR-II B220  and
MAIR-II B220  cells were purified by repeating sorting twice on flow
cytometry ( 99.8% purity). The RNA was extracted from the fraction-
ated and total spleen cells and was subjected to semiquantitive RT-PCR
(30 cycles) for DAP12 and HPRT, according to template dose by dilution.
(B) B cells were purified from spleen cells by repeating positive selection
twice with B220  MACS-beads ( 99.0% purity). 5   106 purified B cells
were stimulated or not with 10  g/ml LPS for 24 h, lysed in 1% NP-40
lysis buffer, and immunoprecipitated with control Ig or anti-DAP12.
Immunoprecipitates or lysates of 106 raw cells were immunoblotted with
anti-DAP12.T
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MAIR-II expressions are required to clarify roles of these
receptors in immune responses.
In the present work, we have shown that cross-linking
MAIR-I and MAIR-II transduces inhibitory and activating
signals, respectively. We have demonstrated the inhibition
of IgE-mediated degranulation by cross-linking MAIR-I
(Fig. 5). This situation is similar in murine PIR-B, an in-
hibitory type of paired Ig-like receptor, which, but not the
activating type PIR-A, is also expressed on mast cells,
where coligation of Fc RI and PIR-B induced inhibition
of IgE-mediated mast cell activation (28). MAIR-I associ-
ates with the phosphatase SHIP, which should be involved
in the inhibition of mast cell activation. However, we do
not conclude which ITIM-like sequence in the cytoplas-
mic region interacts with SHIP to mediate an inhibitory
signal. Although the aa sequences VEYSTL and LHYSSV
fit the consensus sequence for ITIMs (I/V/L/SxYxxL/V),
we cannot exclude a possibility that the YSTL and YSSV
within these sequences consist of ITAM because of the ap-
propriate aa distance for ITAM (eight aa) between the se-
quences (37). In fact, SHIP also associates with ITAM in
several activating adaptors, such as the   and   subunits of
Fc RI, CD3  ,  , and   chains as well as the T cell recep-
tor   chain and Fc  receptor via its SH2 domain (38–40),
although the biological significance of these interactions has
not yet been determined. Nonetheless, MAIR-I mediates
an inhibitory signal and the concrete signaling pathways
mediated by MAIR-I should be clarified in future papers.
On the contrary, MAIR-II associates with the ITAM-
bearing adaptor DAP12 and mediates activating signals for
secretion of inflammatory cytokines and chemokines, such
as TNF-  and MCP-1, but not IL-12, in macrophages.
TNF-  and MCP-1 are secreted from human macrophages
upon initiation of DAP12-dependent pathways via TREM-1,
whereas IL-6 and IL-12 are not (41). Presently, the dis-
crepancy of IL-6 secretion mediated by mouse MAIR-II
and human TREM-1 from macrophages, both of which are
dependent on DAP12 pathways, is unclear. MAIR-II ex-
pression is also observed on a small subset of resting B cells
and up-regulated on the majority of B cells after culture
(Figs. 3, B and E). Because we have demonstrated that B
cells express DAP12 (Fig. 8, A and B), MAIR-II may medi-
ate activation signals via DAP12-dependent pathways in B
cells. Future analyses are required to clarify MAIR-II–medi-
ated signaling and the functional role of MAIR-II in B cells.
Finally, because the MAIR-II  cells coexpress MAIR-I
simultaneously, a question should be raised how activation
or deactivation of these cells is regulated by MAIR-I and
MAIR-II if both receptors would bind the common
ligand. To elucidate the regulatory roles of these receptors
in cell signaling and immune responses, it is essentially re-
quired to identify and characterize the ligands for MAIR-I
and MAIR-II and the receptor–ligand interactions.
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